Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesSTU:4YX0 PB Ratio is 0.39 as of Aug. 07, 2026, which is 64% below its 10-year median of 1.08. The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Rhelion Life Sciences ranks better than 74.27% on this metric.
The historical rank and industry rank for Rhelion Life Sciences's PB Ratio or its related term are showing as below:
STU:4YX0'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.08 Max: 2.78
Current: 0.89
During the past 8 years, Rhelion Life Sciences's highest PB Ratio was 2.78. The lowest was 0.43. And the median was 1.08.
STU:4YX0's PB Ratio is ranked better than 74.27% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs STU:4YX0: 0.89
During the past 12 months, Rhelion Life Sciences's average Book Value Per Share Growth Rate was -33.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.90% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Rhelion Life Sciences was -19.30% per year. The lowest was -25.20% per year. And the median was -20.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rhelion Life Sciences (STU:4YX0) has a PB Ratio of 0.39 as of Aug. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhelion Life Sciences and its competitors. This is 64% below median its historical median of 1.08. Over the past decade, Rhelion Life Sciences' PB Ratio has ranged from 0.43 to 2.78. According to the industry distribution chart, Rhelion Life Sciences ranks #237 out of 921 companies in the Drug Manufacturers industry, placing it in the top 25.7%.
Is Rhelion Life Sciences' PB Ratio too high?
Rhelion Life Sciences' current PB Ratio of 0.39 is 64% below median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 2.78. The Drug Manufacturers industry median PB Ratio is 1.96. Rhelion Life Sciences' value of 0.39 is 80.1% below this industry median. Based on the distribution chart, Rhelion Life Sciences ranks #237 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Rhelion Life Sciences' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #237 out of 921 companies for PB Ratio. This puts Rhelion Life Sciences in the upper half of its industry. The industry median PB Ratio is 1.96. Rhelion Life Sciences' value of 0.39 is 80.1% below this benchmark. Historically, Rhelion Life Sciences' own PB Ratio has ranged from 0.43 to 2.78 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 1.96, Rhelion Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhelion Life Sciences's current PB Ratio of 0.39 is 80.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current PB Ratio is 0.39, which is 64% below median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current PB Ratio is 0.39, which is 64% below median its 10-year median of 1.08 and 80.1% below the Drug Manufacturers industry median of 1.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current PB Ratio is 0.39 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YX0 has been successfully added to your 
